Application of PROTAC strategy to TTR-Aβ protein-protein interaction for the development of Alzheimer’s disease drugs

Alzheimer’s disease (AD) is a complex and multifaced neurodegenerative disorder for which the precise pathological molecular mechanisms are still not completely known. In last years, rational multi-target drug design methods, which combine multiple molecules having complementary modes of action, have been increasingly used in the development of anti-AD drugs. In the present perspective, a new multitarget therapeutic approach, based on an inspired proteolysis targeting chimera (PROTAC) construction, is examined as a future applicable strategy to modulate the favourable cross-interactions between transthyretin and Aβ 1–42 peptide